Literature DB >> 32077470

GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.

Lærke S Gasbjerg1,2, Mads M Helsted2, Bolette Hartmann1,3, Alexander H Sparre-Ulrich1,4, Simon Veedfald1,3, Signe Stensen2, Amalie R Lanng2, Natasha C Bergmann2,5, Mikkel B Christensen2,6,7,8, Tina Vilsbøll2,6,7, Jens J Holst1,3, Mette M Rosenkilde1, Filip K Knop2,3,6,7.   

Abstract

CONTEXT: The actions of both endogenous incretin hormones during a meal have not previously been characterized.
OBJECTIVE: Using specific receptor antagonists, we investigated the individual and combined contributions of endogenous glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) to postprandial glucose metabolism, energy expenditure, and gallbladder motility.
DESIGN: Randomized, double-blinded, placebo-controlled, crossover design.
SETTING: On four separate days, four liquid mixed meal tests (1894 kJ) over 270 minutes (min). PATIENTS OR OTHER PARTICIPANTS: Twelve healthy male volunteers.
INTERVENTIONS: Infusions of the GIP receptor antagonist GIP(3-30)NH2 (800 pmol/kg/min), the GLP-1 receptor antagonist exendin(9-39)NH2 (0-20 min: 1000 pmol/kg/min; 20-270 min: 450 pmol/kg/min), GIP(3-30)NH2+exendin(9-39)NH2, or placebo/saline. MAIN OUTCOME MEASURE: Baseline-subtracted area under the curve (bsAUC) of C-peptide.
RESULTS: Infusion of GIP(3-30)NH2+exendin(9-39)NH2 significantly increased plasma glucose excursions (bsAUC: 261 ± 142 mmol/L × min) during the liquid mixed meals compared with GIP(3-30)NH2 (180 ± 141 mmol/L × min; P = 0.048), exendin(9-39)NH2 (171 ± 114 mmol/L × min; P = 0.046), and placebo (116 ± 154 mmol/L × min; P = 0.015). Correspondingly, C-peptide:glucose ratios during GIP(3-30)NH2+exendin(9-39)NH2 infusion were significantly lower than during GIP(3-30)NH2 (P = 0.0057), exendin(9-39)NH2 (P = 0.0038), and placebo infusion (P = 0.014). GIP(3-30)NH2 resulted in significantly lower AUCs for glucagon than exendin(9-39)NH2 (P = 0.0417). Gallbladder ejection fraction was higher during GIP(3-30)NH2 compared with placebo (P = 0.004). For all interventions, energy expenditure and respiratory quotient were similar.
CONCLUSIONS: Endogenous GIP and GLP-1 lower postprandial plasma glucose excursions and stimulate insulin secretion but only endogenous GIP affects gallbladder motility. The two incretin hormones potentiate each other's effects in the control of postprandial glycemia in healthy men. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  GIP receptor antagonist; GLP-1 receptor antagonist; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; incretin effect; insulin secretion

Year:  2020        PMID: 32077470     DOI: 10.1210/clinem/dgz175

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection.

Authors:  Peter Lindquist; Lærke Smidt Gasbjerg; Jacek Mokrosinski; Jens Juul Holst; Alexander Sebastian Hauser; Mette Marie Rosenkilde
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

Review 2.  The incretin/glucagon system as a target for pharmacotherapy of obesity.

Authors:  Stefano Del Prato; Baptist Gallwitz; Jens Juul Holst; Juris J Meier
Journal:  Obes Rev       Date:  2021-10-28       Impact factor: 10.867

Review 3.  Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome.

Authors:  Kleopatra Alexiadou; Tricia M-M Tan
Journal:  Curr Diab Rep       Date:  2020-05-21       Impact factor: 4.810

Review 4.  Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.

Authors:  Jonathan E Campbell
Journal:  Mol Metab       Date:  2020-12-05       Impact factor: 7.422

5.  Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer's Disease.

Authors:  Jelena Osmanovic Barilar; Ana Knezovic; Jan Homolak; Ana Babic Perhoc; Melita Salkovic-Petrisic
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

6.  Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.

Authors:  Jens Juul Holst
Journal:  Diabetes       Date:  2021-11       Impact factor: 9.461

Review 7.  Targeting fibrosis, mechanisms and cilinical trials.

Authors:  Manyu Zhao; Liqun Wang; Mengzhu Wang; Shijie Zhou; Ying Lu; Huijie Cui; Alexandra C Racanelli; Ling Zhang; Tinghong Ye; Bisen Ding; Ben Zhang; Jinliang Yang; Yuqin Yao
Journal:  Signal Transduct Target Ther       Date:  2022-06-30

Review 8.  Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

Authors:  Michael A Nauck; David A D'Alessio
Journal:  Cardiovasc Diabetol       Date:  2022-09-01       Impact factor: 8.949

9.  Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.

Authors:  Mona Mashayekhi; Jessica R Wilson; Scott Jafarian-Kerman; Hui Nian; Chang Yu; Megan M Shuey; James M Luther; Nancy J Brown
Journal:  Diabetes Obes Metab       Date:  2020-10-22       Impact factor: 6.408

Review 10.  Repositioning the Alpha Cell in Postprandial Metabolism.

Authors:  Kimberley El; Megan E Capozzi; Jonathan E Campbell
Journal:  Endocrinology       Date:  2020-11-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.